Department of Stroke Medicine, Kawasaki Medical School, Kurashiki, Japan.
J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):864-8. doi: 10.1136/jnnp.2009.190140. Epub 2010 Jun 19.
Clinical-diffusion mismatch (CDM) between stroke severity and volume of diffusion-weighted imaging (DWI) lesions seems to predict penumbra. The Alberta Stroke Program Early CT Score on DWI (DWI ASPECTS) is a simple score for identifying ischaemic lesions. The authors examined whether CDM using DWI ASPECTS can predict neurological improvement in patients with acute stroke treated with intravenous tissue plasminogen activator (t-PA).
The authors enrolled consecutive patients with anterior circulation stroke treated with intravenous t-PA. The authors calculated a cut-off value for CDM using DWI ASPECTS. After excluding a group of patients with mild symptoms (National Institutes of Health Stroke Scale (NIHSS) score <8), the authors divided the patients into two groups by presence or not of CDM (a positive group (P-CDM) and a negative group (N-CDM)). The authors then compared clinical characteristics including NIHSS score and modified Rankin Scale at 90 days after intravenous t-PA.
Seventy-one patients (male 41, mean age 74 years) were enrolled. DWI ASPECTS was linearly related to DWI lesion volume. The authors defined CDM as NIHSS scores > or =8 and DWI ASPECTS > or =7. The P-CDM group had 35 patients (61%) and the N-CDM group 22 patients (39%). NIHSS scores on admission were 15 (median) in P-CDM and 20 in N-CDM (p=0.004). NIHSS scores after intravenous t-PA improved in P-CDM but were unchanged in N-CDM (7 vs 20 at 7 days, p=0.033 on ANOVA). A favourable outcome at 90 days, defined as modified Rankin scale 0-3, was found in 46% of P-CDM patients and 14% of N-CDM patients (p=0.020).
CDM determined using DWI ASPECTS may be associated with neurological improvement in patients treated with intravenous t-PA.
卒中严重程度与弥散加权成像(DWI)病变体积之间的临床-弥散不匹配(CDM)似乎可以预测半暗带。 Alberta 卒中计划 DWI 早期 CT 评分(DWI ASPECTS)是一种简单的评分方法,用于识别缺血性病变。作者研究了使用 DWI ASPECTS 的 CDM 是否可以预测接受静脉内组织型纤溶酶原激活剂(t-PA)治疗的急性卒中患者的神经功能改善。
作者连续纳入接受静脉内 t-PA 治疗的前循环卒中患者。作者计算了使用 DWI ASPECTS 的 CDM 的截止值。排除一组症状较轻的患者(NIHSS 评分<8)后,作者根据是否存在 CDM 将患者分为两组(阳性组(P-CDM)和阴性组(N-CDM))。然后,作者比较了包括静脉内 t-PA 后 90 天 NIHSS 评分和改良 Rankin 量表在内的临床特征。
共纳入 71 例患者(男性 41 例,平均年龄 74 岁)。DWI ASPECTS 与 DWI 病变体积呈线性相关。作者将 CDM 定义为 NIHSS 评分≥8 和 DWI ASPECTS≥7。P-CDM 组有 35 例患者(61%),N-CDM 组有 22 例患者(39%)。P-CDM 组入院时 NIHSS 评分为 15(中位数),N-CDM 组为 20(p=0.004)。P-CDM 组静脉内 t-PA 后 NIHSS 评分改善,而 N-CDM 组无变化(7 天时为 7 分,20 分,ANOVA 检验 p=0.033)。90 天时的良好结局定义为改良 Rankin 量表 0-3 分,P-CDM 组有 46%的患者和 N-CDM 组有 14%的患者达到(p=0.020)。
使用 DWI ASPECTS 确定的 CDM 可能与接受静脉内 t-PA 治疗的患者的神经功能改善相关。